Phase II Study of TKI258 in Advanced Urothelial Carcinoma
NCT00790426
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Urothelial Cancer
Interventions
DRUG:
TKI258
Sponsor
Novartis Pharmaceuticals